Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HIV-1 Peptide Vaccine, Microparticulate Monovalent · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HIV-1 Peptide Vaccine, Microparticulate Monovalent | BIOLOGICAL | - |
| rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine | BIOLOGICAL | - |
Inclusion Criteria Volunteers must have: * Normal history and physical exam. * HIV negativity. * CD4 count \>= 400 cells/mm3. * Intermediate or high risk sexual behavior or a history of injection drug use within 12 months prior to study entry. * Normal urine dipstick with esterase and nitrite. Ex...
Top 20 of 28 competitors
HIV-1 Peptide Vaccine, Microparticulate Monovalent is an investigational vaccine being studied for the prevention of HIV infections. It is designed for HIV-1 seronegative individuals, meaning those who do not have HIV. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
HIV-1 Peptide Vaccine, Microparticulate Monovalent is being developed by United Therapeutics Corporation, a company traded on the NASDAQ under the ticker symbol UTHR. The vaccine is in Phase 1 clinical development for HIV infections.
HIV-1 Peptide Vaccine, Microparticulate Monovalent is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA. The vaccine is being studied for its safety and immunogenicity in HIV-1 seronegative subjects.
HIV-1 Peptide Vaccine, Microparticulate Monovalent has one completed clinical trial, identified as NCT00002428. This was a Phase I/II safety and immunogenicity trial of the UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 seronegative human subjects, conducted in the United States.
HIV-1 Peptide Vaccine, Microparticulate Monovalent is classified as a monoclonal antibody modality, though it is a vaccine designed to elicit an immune response against HIV-1. It is being developed as a preventive vaccine for HIV infections and is currently in Phase 1 clinical trials.